Use of a Modified α-N-Acetylgalactosaminidase in the Development of Enzyme Replacement Therapy for Fabry Disease  by Tajima, Youichi et al.
ARTICLEUse of a Modified a-N-Acetylgalactosaminidase
in the Development of Enzyme Replacement Therapy
for Fabry Disease
Youichi Tajima,1,3 Ikuo Kawashima,1,3 Takahiro Tsukimura,2,3 Kanako Sugawara,1 Mayuko Kuroda,2
Toshihiro Suzuki,2 Tadayasu Togawa,2 Yasunori Chiba,4 Yoshifumi Jigami,4 Kazuki Ohno,5
Tomoko Fukushige,6 Takuro Kanekura,6 Kohji Itoh,7 Toya Ohashi,8 and Hitoshi Sakuraba1,2,*
A modiﬁed a-N-acetylgalactosaminidase (NAGA) with a-galactosidase A (GLA)-like substrate speciﬁcity was designed on the basis of
structural studies and was produced in Chinese hamster ovary cells. The enzyme acquired the ability to catalyze the degradation of
4-methylumbelliferyl-a-D-galactopyranoside. It retained the original NAGA’s stability in plasma and N-glycans containing many
mannose 6-phosphate (M6P) residues, which are advantageous for uptake by cells via M6P receptors. There was no immunological
cross-reactivity between the modiﬁed NAGA and GLA, and the modiﬁed NAGA did not react to serum from a patient with Fabry disease
recurrently treated with a recombinant GLA. The enzyme cleaved globotriaosylceramide (Gb3) accumulated in cultured ﬁbroblasts from
a patient with Fabry disease. Furthermore, like recombinant GLA proteins presently used for enzyme replacement therapy (ERT) for
Fabry disease, the enzyme intravenously injected into Fabry model mice prevented Gb3 storage in the liver, kidneys, and heart and
improved the pathological changes in these organs. Because this modiﬁed NAGA is hardly expected to cause an allergic reaction in Fabry
disease patients, it is highly promising as a new and safe enzyme for ERT for Fabry disease.
Introduction
Fabry disease (MIM 301500) is an X-linked genetic dis-
ease caused when a deﬁciency of a-galactosidase A (GLA,
MIM 300644, EC3.2.1.22) activity results in lysosomal
accumulation of globotriaosylceramide (Gb3; also called
ceramide trihexoside, CTH).1 The disease exhibits a wide
range of clinical phenotypes, from the early-onset severe
‘‘classic form’’ to the late-onset moderate one called the
‘‘variant form.’’ Having no GLA activity, patients with
the classic form develop pain in the peripheral extremities,
hypohidrosis, angiokeratomas, and corneal opacities, and
there is also renal and cardiac involvement. Patients with
the variant form have residual GLA activity and develop
milder clinical manifestations, sometimes limited to heart
disorders.1 Recently, a high incidence (1 in ~3,000) of this
disease was revealed in newborn screening,2 and the clin-
ical importance of this disease is being increasingly recog-
nized.
So far, two different recombinant GLAs have been devel-
oped for enzyme replacement therapy (ERT) for Fabry
disease: agalsidase beta (Fabrazyme; Genzyme Therapeu-
tics, Cambridge, MA), generated in Chinese hamster ovary
(CHO) cells,3,4 and agalsidase alfa (Replagal; Shire HGT,
Cambridge, MA), produced in cultured human ﬁbro-
blasts.5 They are intravenously injected into patients
with Fabry disease every 2 weeks and are expected to be
incorporated into cells via mannose 6-phosphate (M6P)
receptors on the plasma membrane and then transported
to lysosomes.6 Although many patients have been success-
fully treated with these recombinant GLA proteins, many
problems remain to be resolved, i.e., (1) these drugs are
unstable in blood7, (2) they are not well incorporated
into target organs, including the kidneys and heart7, and
(3) because most male patients with Fabry disease do not
have any GLA proteins, repeated injection of recombinant
enzymes frequently results in an allergic reaction.4,5
Furthermore, development of antibodies against the
recombinant GLAs sometimes decreases the effects of the
enzymes.8–10
In this study, we altered the substrate speciﬁcity of a-N-
acetylgalactosaminidase (NAGA, MIM 104170, EC3.2.1.49),
which had been previously called a-galactosidase B11
because themodiﬁed enzyme is similar in protein structure
to NAGA but displays catalytic activity toward Gb3, by
making structure-based amino acid substitutions in the
active site to develop a new recombinant enzyme for ERT
for Fabry disease.
Material and Methods
The study involving the human serum and cultured ﬁbroblasts
was approved by the ethical committee of our institute. The study
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involving mice was performed according to the rules drawn up by
the animal care committee of our institute.
Molecular Design of a Modiﬁed NAGA
Structural modeling of human NAGA was performed with molec-
ular modeling software Jackal.12 The crystal structure of chicken
NAGA (PDB code: 1KTB)13 was used as a template, and energy
minimization was performed. The root-mean-square gradient
value was set at 0.05 kcal/mol/A˚. The new structure was then com-
pared with the human GLA structure (PDB code: 1R47)14, and the
difference between the structures of their respective active sites
was examined. Then, target amino acid residues for altering the
substrate speciﬁcity were determined, and a structural model of
the modiﬁed NAGA was built with TINKER.15–18 Then, cDNA for
the modiﬁed NAGA (DDBJ: AB522713) was designed.
GLA and NAGA Assays and Protein Determination
ForﬂuorometricmeasurementofGLA-degrading activity, 4-methy-
lumbelliferyl (MU)-a-D-galactopyranoside (Calbiochem, LaJolla,
CA) was used as a substrate, and N-acetyl-D-galactosamine
(Sigma-Aldrich, St. Louis, MO) was used as an inhibitor of
NAGA.19 NAGA-degrading activity was ﬂuorometrically measured
withMU-a-D-N-acetylgalactosamine (MU-2-acetamide-2-deoxy-a-
D-galactopyranoside; Toronto Research Chemicals, North York,
ON, Canada) as a substrate.20 Both the GLA and the NAGA assay
were conducted with a Wallac 1420 ARVO MX multilabel counter
(Perkin Elmer, Waltham, MA) at excitation and emission wave-
lengths of 355 nm and 460 nm, respectively. Protein concentra-
tions were determined with a Micro BCA Protein Assay Reagent
Kit (PIERCE, Rockfold, IL), and bovine serum albumin was used
as a standard.
Preparation of a Retrovirus Vector for Expression
of the Modiﬁed NAGA
Human NAGA cDNA (Open Biosystems, Huntsville, AL; GenBank
accession: BC000095, I.M.A.G.E.: 3504221)was used as a template.
The coding region for human NAGA was ampliﬁed by PCR with
the following primers and then introduced into a retrovirus vec-
tor, pCX4neo21: NAGA sense, 50-GATGCTGCTGAAGACATGGCT
CTT-30; and NAGA antisense, 50-TCACTGCTGGGACTACTCCAG
GTT-30. To generate a modiﬁed NAGA with altered substrate spec-
iﬁcity, we performed site-directed mutagenesis with a Gene Tailor
site-directed mutagenesis kit (Invitrogen, Carlsbad, CA) according
to the manufacturer’s instructions. pCX4neo-NAGA was used as a
template with the following primers: S188E sense, 50-CCCATC
GCCTTCTCCTGCGAGTGGCCAGCCTATGA-30; S188E antisense,
50-GCAGGAGAAGGCGATGGGGCGGCCTGT-30. Then pCXneo-
NAGA S188E was used as a template with the following primers:
A191L sense, 50-TTCTCCTGCGAGTGGCCACTCTATGAAGGCGG
CCT-30; and A191L antisense, 50-TGGCCACTCGCAGGAGAAGGC
GATGGGG-30. The italicized nucleotides are the mutated sites.
The site-directed mutagenesis was conﬁrmed via sequencing in
both directions.
Retrovirus-Mediated Gene Transfer to Human Fabry
Fibroblasts
Retrovirus vector plasmids, pCX4neo-NAGA and pCX4neo-modi-
ﬁed NAGA, were used for transfection of Phoenix Ampho, an am-
photropic human leukemia virus-packaging cell line,22 by means
of Dofect-GT1 (Dojindo, Kumamoto, Japan) according to the
manufacturer’s directions. Two days after the transfection, culture570 The American Journal of Human Genetics 85, 569–580, Novemsupernatants were collected, ﬁltered, supplemented with 2 mg/ml
polybrene (Sigma-Aldrich), and then used for infection. Infection
was carried out through the addition of a retrovirus solution of
pCX4neo-NAGA or pCX4neo-modiﬁed NAGA to the culture
medium of Fabry ﬁbroblasts. Two days after the infection, infected
cells were selected in 250 mg/ml of G418 disulfate (GIBCO, Grand
Island, NY) for 14 days or more. The G418-resistant populations of
human Fabry ﬁbroblasts were used for determining the MU-a-D-
galactopyranoside- andMU-a-D-N-acetylgalactosamine-degrading
activities.
Preparation of a Modiﬁed NAGA Construct via
a Glutamine Synthetase Gene-Expression System
pCX4neo-modiﬁed NAGA was used as a template. The coding
region for the modiﬁed NAGA was ampliﬁed by PCR with the
following primers: HindIII-NAGA sense, 50-CCCAAGCTTGATG
CTGCTGAAGACAGTGCTCTT-30; and EcoRI-NAGA antisense,
50-GGAATTCTCACTGCTGGGACATCTCCAGGTT-30. The itali-
cized nucleotides are the HindIII and EcoRI sites, respectively.
PCR fragments of the modiﬁed NAGA cDNA were introduced
into the pEE14.4 vector (Lonza Biologics, Allendale, NJ). Further-
more, so that the secretion would be enhanced, a modiﬁed
NAGA was generated by replacement of the amino terminus
(amino acids 1–17) with the signal peptide of human GLA (amino
acids 1–31). Overlap extension was performed by PCR. First, to
generate a PCR product of the GLA signal, we ampliﬁed the GLA
signal sequence by performing PCR with the following primers:
Hind III-GLA sense, 50-CCCAAGCTTATGCAGCTGAGGAACCCA
GAA-30; and NAGA-GLA antisense, 50-GTCCAGTGCTCTAGCCC
CAG-30. pCXN2-Gal, which cloned the full-length human
GLA cDNA23, was used as a template. Second, to generate a PCR
product of the modiﬁed NAGA minus its signal sequence, we
ampliﬁed it by conducting PCR with the following primers:
GLA-NAGA sense, 50-TCACTGCTGGGACATCTCCAGGTT-30; and
EcoRI-NAGA antisense, 50-GGAATTCTCACTGCTGGGACATCTC
CAGGTT-30. pCX4neo-modiﬁed NAGA was used as a template.
The italicized nucleotides and the underlined nucleotides are the
restriction sites and overlapping regions, respectively. Third, to
generate a modiﬁed NAGA with the GLA signal sequence, we per-
formed overlap extension by conducting PCR with Hind III-GLA
sense and EcoRI-NAGA antisense primers and using the ﬁrst and
second PCR products as templates. The PCR fragment of GLA
signal-modiﬁed NAGA cDNA was introduced into the pEE14.4
vector.
Generation of Stable Cell Lines Expressing
the Modiﬁed NAGA
CHO cells stably expressing the modiﬁed NAGA were generated
with a glutamine synthetase gene-expression system (Lonza Bio-
logics) and cloned according to the manufacturer’s protocol.
Puriﬁcation of the Modiﬁed NAGA
CHO cells stably expressing the modiﬁed NAGA and secreting it
into the medium were at ﬁrst cultured in Dulbecco’s modiﬁed
Eagle’s medium without glutamine (GIBCO) but containing 10%
dialyzed fetal bovine serum (FBS), glutamine synthetase supple-
ment (SAFC Bioscience, Leneva, KS), and 1 mM L-methionine sul-
foximine (MSX; Sigma-Aldrich) at 37C in an incubator containing
5%CO2. Then themediumwas changed toCDOpti-CHOmedium
(GIBCO) containing 1% dialyzed FBS, glutamine synthetase
supplement, and 1 mMMSX, and the conditioned culture mediumber 13, 2009
was harvested every week. The collected medium was clariﬁed,
concentrated via an ultraﬁltration membrane (Millipore Corpora-
tion, Bedford,MA), and then precipitatedwith ammonium sulfate.
The precipitate was dissolved, then subjected to column chroma-
tography on HiLoad 26/10 phenyl-Sepharose, HiLoad 26/10 SP-
Sepharose, andHiLoad26/10Q-SepharoseHPcolumns (GEHealth-
care Bio-Sciences, Piscataway, NJ), and the fractions showing
MU-a-D-galactopyranoside-degrading activity were collected.
Biochemical Analyses of the Modiﬁed NAGA
The purity and molecular mass of the modiﬁed NAGA were deter-
mined by sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) followed by staining with Coomassie brilliant
blue R. Deglycosylation of the enzyme was performed with an
enzymatic deglycosylation kit (Prozyme, San Lendodro, CA)
including glycopeptidase F (PNGase F). As controls, placenta
NAGA (a gift from Dr. A. Tsuji, University of Tokushima), agalsi-
dase beta, and agalsidase alfa were used. The enzyme proteins
were electrophoresed on a Tris-glycine polyacrylamide gel
(Cosmo-bio, Tokyo, Japan) and then stained with Coomassie bril-
liant blue R. Immunoblotting analyses with anti-NAGA polyclonal
antibodies20 and anti-GLA polyclonal antibodies24 were per-
formed. The monosaccharide compositions of N-glycans of the
modiﬁed NAGA were determined by means of capillary electro-
phoresis with a P/ACE MDQ equipped with a laser-induced ﬂuo-
rescence detector (Beckman Coulter, Fullerton, CA) after digestion
with PNGase F (TAKARA BIO, Shiga, Japan). GLA-degrading
activity was measured with MU-a-D-galactopyranoside as a
substrate, and NAGA-degrading activity was measured with
MU-a-D-N-acetylgalactosamine as a substrate as described above.
We performed a kinetic experiment with the modiﬁed NAGA
and various concentrations of the substrate to determine the
Vmax and Km values; agalsidase beta and agalsidase alfa served
as controls, as described previously.25
Examination of Immune Reaction of the Modiﬁed
NAGA to Fabry Serum
To determine whether the modiﬁed NAGA reacts with anti-GLA
serum, we performed a solid-phase enzyme-linked immunosor-
bent assay (ELISA). A serum sample was obtained from a Fabry
patient who had been repeatedly injected with agalsidase beta
(titer of the antibodies against the recombinant GLAs, 12,8003).
In brief, a 96-well ﬂat-bottom microplate for ELISA (Maxisorp;
Nunk, Rockilde, Denmark) was coated with 100 ml of modiﬁed
NAGA (1, 3, and 10 mg/ml), agalsidase beta (1 and 3 mg/ml), and
agalsidase alfa (1 and 3 mg/ml) at 4C overnight. After the wells
were washed with phosphate-buffered saline (PBS), 250 ml of Block
Ace (diluted 1:4; DS Pharma Biomedical, Osaka, Japan) was added
to each well as a blocking solution, and incubation followed for
1 hr at room temperature. After removal of the blocking solution,
each well was washed with 0.1% Tween 20 in PBS (PBS-T). Then
150 ml of the patient’s serum (diluted 1:1,000 or 1:10,000) was
added to each well, and incubation followed for 1 hr at room
temperature. The wells were then washed, incubated in 200 ml of
peroxidase-conjugated anti-human IgG (diluted 1:50,000; Jackson
Immuno Research, West Grove, PA) for 1 hr at room temperature,
washed again, and then incubated in 100 ml peroxidase substrate
(SAT Blue; Dojindo) for 5 min at room temperature. Then, 50 ml
of a stopping solution (2 MH2SO4) was added, and the absorbance
of each well was measured by means of a microplate reader
(Benchmark; BioRad, Hercules, CA).The AmericanStability of the Modiﬁed NAGA
To assess the stability of the modiﬁed NAGA, agalsidase beta, and
agalsidase alfa at various pHs, we added each of these to 10 mM
sodium citrate buffer (pH 4.0), 10 mM sodium acetate buffer
(pH 4.5 and 5.0), 10 mM citric acid/sodium phosphate buffer
(pH 5.5, 6.0 and 6.5), or 10 mM phosphate buffer (pH 7.0, 7.5
and 8.0) so that the result was 2 mmol/h/ml of MU-a-D-galactopyr-
anoside-degrading activity. Incubation followed at 37C for 16 hr.
The enzyme activity at time zero was taken to be 100% under each
pH condition in a buffer, and the stabilities of themodiﬁed NAGA,
agalsidase beta, and agalsidase alfa were calculated as the ratio
(percent) of the enzyme activity after a 16 hr incubation to the
level at time zero. Furthermore, we examined the stabilities of
the enzymes under pH 4.5 and 7.0 conditions in a buffer and in
plasma at 37C by following the time course. The stabilities of
the enzymes were expressed as the ratio (percent) of the enzyme
activity at a particular incubation time point to the value at time
zero.
Examination of the Effect of the Modiﬁed NAGA
on Cultured Fabry Fibroblasts
The effect of the modiﬁed NAGA on cleavage of the Gb3 that had
accumulated in cultured ﬁbroblasts from a patient with Fabry
disease was examined. Previously, Ries et al. reported that the
GLA activity in plasma reached 1–10 mmol/h/ml within 30 min
after the administration of agalsidase alfa to Fabry patients.26
Therefore, we added the modiﬁed NAGA and each of the recombi-
nantGLAs to the culturemediumof cells to obtain a concentration
of 5 mmol/h/ml. For examination of the inhibitory effect of M6P
on the cellular uptake of the modiﬁed NAGA, Fabry ﬁbroblasts
were cultured in medium containing 5 mMM6P and the modiﬁed
NAGA. The cells were cultured for 72 hr, and then immunostain-
ing of the accumulated Gb3 with an anti-Gb3 mouse monoclonal
antibody (mAb)27 was performed, as described previously.7,24
Examination of the Effect of the Modiﬁed NAGA
on Fabry Mice
Fabry mice (GLA knock-out mice donated by A.B. Kulkarni and
T. Ohshima, et al.)28,29 and wild-type C57BL/6 mice were used in
this experiment. We examined the biodistribution of the enzyme.
In a previously reported animal experiment30, a single dose of
recombinant GLA at 0.3–10mg/kg body weight was used for a bio-
distribution study. Here, a single dose (2 mmol/h/kg body weight)
of the modiﬁed NAGA was injected into a tail vein of each Fabry
mouse. As controls, agalsidase beta and agalsidase alfa were
injected into litter-matched Fabrymice; the activity of the injected
enzymewas the same as for themodiﬁedNAGA.7,24 Themice were
sacriﬁced 1 hr after administration of the enzymes, and then
the MU-a-D-galactopyranoside-degrading activity in the liver,
kidneys, and heart was measured.
To examine cleavage of the Gb3 accumulated in organs,
we repeatedly injected Fabry mice with the modiﬁed NAGA
(2mmol/h/kg bodyweight) every day for seven days and sacriﬁced
mice 24 hr after the last injection. The liver, kidneys, and heart
were then removed as samples for immunostaining, biochemical
Gb3-determination, and electron microscopy. For immunohisto-
chemical analysis, frozen sections of 8 mm thickness were ﬁxed
with 4% PFA in PBS for 30 min and then blocked with 10%
M.O.M. mouse Ig Blocking Reagent (Vector Laboratories, Burlin-
game, CA) in PBS for 2 hr. The specimens were then incubated
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mouse mAb27 at 4C overnight. After being washed in PBS-T, the
specimens were further incubated with an Alexa Fluor 488-conju-
gated goat anti-mouse IgG F(ab0)2 (diluted 1:1,000; Molecular
Probes, Eugene, OR) for 1 hr. The specimens were embedded in
PermaFlour (Thermo Electron Corporation,MA). The stained spec-
imens were observed under a microscope (Axiovert 135; Carl Zeiss,
Oberkochen, Germany) equipped with an Axio Vision 3.1 system.
For determination of their Gb3 levels, the liver, kidneys, and heart
were analyzed by means of thin-layer chromatography (TLC) fol-
lowed by densitometry, as described previously.31 For morpholog-
ical analysis, electron microscopy was performed as described
previously.7,24
Statistical Analyses
Data are expressed as means 5 standard deviation (SD). We per-
formed statistical analyses with a Student’s t test. Values were
considered statistically signiﬁcant at p < 0.05.
Results
Structure-Based Design of a Modiﬁed NAGA
A structural model of human NAGA was built on the basis
of the crystallographic structure data for chicken NAGA,
which exhibits 75% amino acid identity (Figure 1B). The
resulting model was compared with the crystal structure
of human GLA (Figure 1A), especially regarding the active
site. It was revealed that Glu203 and Leu206 play impor-
tant roles in the recognition of a galactose residue in
GLA (Figure 1D) and that Ser188 and Ala191 play impor-
tant roles in the recognition of an N-acetylgalactosamine
residue in NAGA (Figure 1E). Therefore, we replaced
Ser188 and Ala191 of NAGA with Glu and Leu, respec-
tively, to alter the substrate speciﬁcity and thereby
designed a modiﬁed NAGA (Figures 1C and 1F).
Figure 1. Structures of GLA, NAGA, and
the Modified NAGA
The whole structures and those of the
active sites of GLA (A and D), NAGA
(B and E), and the modiﬁed NAGA (C
and F) are shown as ribbon models.
Each is presented as a complex with its
substrate.
Table 1. Expression Study on the NAGA andModifiedNAGA cDNAs
Cells
Introduced
cDNA
MU-a-D-
Galactopyranoside-
Degrading Activity
(nmol/h/mg protein)
MU-a-D-N-
Acetylgalactosamine-
Degrading Activity
(nmol/h/mg protein)
Wild type - 30 2.5 3 102
Kanzaki - 40 <1.0
Fabry - 2.0 2.3 3 102
NAGA 13 1.3 3 104
modiﬁed
NAGA
5.5 3 102 1.0 3 102
Wild type, human cultured fibroblasts from an apparently normal subject; Kan-
zaki, cultured fibroblasts from a patient with Kanzaki disease (inherited NAGA
deficiency); and Fabry, cultured fibroblasts from a patient with Fabry disease.
Expression of the Modiﬁed NAGA
cDNA in Cultured Fabry
Fibroblasts
On the basis of this structure-based
design, we at ﬁrst constructed a
cDNA encoding the modiﬁed NAGA
and having its own signal sequence,
introduced it into an expression
vector, and then expressed it in
cultured ﬁbroblasts from a patient
with Fabry disease. An expression
study showed that the two amino
acid substitutions in the active site
of NAGA resulted in alteration of its substrate preference
(Table 1).
Production and Puriﬁcation of the Modiﬁed NAGA
To produce a sufﬁcient amount of the modiﬁed NAGA
protein in CHO cells, the cDNA encoding the modiﬁed
NAGA and having its own signal sequence was introduced
into an expression vector, pEE14.4. Furthermore, to
enhance the secretion of the enzyme, we replaced the
signal sequence region of NAGA with that of GLA, which
should be cleaved at an early stage of biosynthesis. Then,
the vector was transfected into CHO cells. CHO cells stably
expressing the modiﬁed enzyme were obtained via a gluta-
mine synthetase gene expression system. The productivity
was estimated to be approximately 10 mg/liter.
Then, the enzyme was puriﬁed from conditioned culture
medium containing the modiﬁed NAGA protein by means
of column chromatography. The puriﬁcation degree was572 The American Journal of Human Genetics 85, 569–580, November 13, 2009
Table 2. Purification of the Modified NAGA from Conditioned Culture Medium
Total Protein (g) Total Activity (mmol/h) Specific Activity (mmol/h/mg) Relative Purity Yield (Percent)
Medium concentration 61 55 0.9 1.0 100
Dialyzed 50% 28 53 1.9 2.1 96
(NH4)2SO4 fraction
Phenyl-Sepharose 3.3 34 10 12 63
SP-Sepharose 0.13 22 1.7 3 102 1.9 3 102 40
Flow-through
Q-Sepharose 0.042 21 5.0 3 102 5.6 3 102 38560-fold, and the recovery of the enzyme protein was 38%
(Table 2).
Enzymological Characterization of the Modiﬁed
NAGA
The puriﬁed modiﬁed NAGA was enzymologically charac-
terized. The degrading activity toward MU-a-D-galactopyr-
anoside, an artiﬁcial substrate for GLA, of the modiﬁed
NAGA was 0.5 mmol/h/mg protein; this value was about
a quarter of those of agalsidase beta and agalsidase alfa.
The Km value of the modiﬁed NAGA was 4.8 mM, which
was slightly higher than those of agalsidase beta and agal-
sidase alfa (4.0 mM). The modiﬁed NAGA hardly exhibited
any hydrolyzing activity toward MU-a-N-acetylgalactos-
amine, an artiﬁcial substrate for NAGA (Table 3).
The modiﬁed NAGA was detected as two or more broad
bands on SDS-PAGE, but it only gave one band after degly-
cosylation, suggesting that it has heterogeneous sugar
chains (Figure 2). The results of immunoblotting revealed
that there was no immunological cross-reactivity between
the modiﬁed NAGA and a recombinant GLA protein
(Figure 3). The content of M6P, which is very important
for incorporation of the enzyme into cells, was 5.1 mol/
mol protein for the modiﬁed NAGA, and this value was
higher than those for both agalsidase beta (3.6 mol/mol
protein) and agalsidase alfa (2.1 mol/mol protein) (p <
0.05, t test, Table 4).
The stability of the modiﬁed NAGA in buffer and human
plasma was examined in vitro. The results revealed that the
modiﬁed NAGA was more stable under both acidic andThe Americanneutral pH conditions in a buffer (p < 0.05, t test, Figures
4A–4C) and also in human plasma (p < 0.05, t test,
Figure 4D) than agalsidase beta and agalsidase alfa.
Immunoreactivity of theModiﬁed NAGA to the Serum
from a Fabry Patient
The immunoreactivity of the modiﬁed NAGA to the serum
from a Fabry patient who had been repeatedly injected
with agalsidase beta was examined by means of ELISA.
The serum strongly reacted to the recombinant GLAs, agal-
sidase beta and agalsidase alfa, but not to the modiﬁed
NAGA (Figure 5).
Effect of the Modiﬁed NAGA on Cultured Fabry
Fibroblasts
The effect of the modiﬁed NAGA on cleavage of the Gb3
that had accumulated in Fabry ﬁbroblasts was examined
by means of immunostaining for Gb3 and was compared
with the effects of agalsidase beta and agalsidase alfa. The
results are shown in Figure 6. The modiﬁed NAGA and
the two recombinant GLAs were each added to the culture
medium at the concentration giving an activity level of 5
mmol/h/ml. The cells were cultured at 37C for 72 hr and
then stained with anti-Gb3 mouse mAb. The immunoﬂuo-
rescence of Gb3 apparently decreased with the addition of
the modiﬁed NAGA, and there were no differences in Gb3-
degrading activity between the modiﬁed NAGA and the
two recombinant GLAs. The cleavage of the accumulated
Gb3 by the modiﬁed NAGA was almost completely in-
hibited by the addition of 5 mM M6P, suggesting thatTable 3. Enzymological Parameters of the Modified NAGA
MU-a-D-Galactopyranoside-Degrading Activity MU-a-D-N-Acetylgalactosamine-Degrading Activity
Specific Activity (mmol/h/mg) Vmax (mmol/h/mg) Km (mM) Specific Activity (mmol/h/mg)
Modiﬁed NAGA 0.5 1.0 4.8 3.0
Placenta NAGAa <0.01 - - 24
Agalsidase beta 2.3 3.8 4.0 <1.0
Agalsidase alfa 2.1 3.8 4.0 <1.0
As controls, NAGA from placenta, agalsidase beta, and agalsidase alfa were used.
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incorporation of the modiﬁed NAGA depends on M6P
receptors.
Effect of the Modiﬁed NAGA on Fabry Mice
We injected the modiﬁed NAGA into the tail veins of Fabry
mice to compare its therapeutic effect with those of agalsi-
dase beta and agalsidase alfa. Because the speciﬁc enzyme
activity differed among the enzymes, we injected amounts
of the enzymes exhibiting almost the same activity
(2 mmol/h/kg body weight) into litter-matched Fabry
mice for comparison, according to the method previously
reported.7,24
At 1 hr after administration of a single dose of each
enzyme, the mice were sacriﬁced, and MU-a-D-galactopyr-
anoside-degrading activity in the liver, kidneys, and heart
was determined. An apparent increase in the enzyme
activity was observed in these organs of Fabry mice after
the modiﬁed NAGA administration. The enzyme activity
increased up to 6, 4, and 5 times that in the liver, kidneys,
and heart, respectively, of the wild-type mice. The
increases in the enzyme activity were greater in the kidneys
(p¼ 0.005 and 0.003 for a comparison with agalsidase beta
and agalsidase alfa, respectively, t test) and heart (p¼ 0.001
and 0.003 for a comparison with agalsidase beta and agal-
sidase alfa, respectively, t test), and similar in the liver
(Figure 7).
The effect of administration of the modiﬁed NAGA on
degradation of the Gb3 that had accumulated in tissues
was examined after repeated injection of the enzyme at
2 mmol/h/kg body weight every day for 7 days, followed
Figure 2. Coomassie Brilliant Blue R Staining of the Modified
NAGA on a Tris-Glycine Polyacrylamide Gel
Before the electrophoresis, the enzyme was treated (PNGase Fþ) or
not treated (PNGase F) with glycopeptidase F. As controls, NAGA
puriﬁed from human placenta (Placenta NAGA), agalsidase beta
(Agalsidase beta), and agalsidase alfa (Agalsidase alfa) were used.574 The American Journal of Human Genetics 85, 569–580, Novembby killing of the mice 24 hr after the last injection. Immu-
nohistochemical analysis revealed that the Gb3 that had
accumulated in the liver was almost completely hydro-
lyzed. In both the kidney and heart tissues, the Gb3 immu-
noﬂuorescence was apparently decreased. These ﬁndings
were essentially the same as those in the cases of adminis-
tration of agalsidase beta and agalsidase alfa (Figure 8). The
results of TLC analysis also revealed that the modiﬁed
NAGA cleaved the Gb3 accumulated in the liver, kidneys,
and heart (Table 5).
Figure 3. Immunoblotting of the Modified NAGA, Agalsidase
Beta, and Agalsidase Alfa
ThemodiﬁedNAGA, agalsidase beta, and agalsidase alfa were sepa-
rated on a Tris-glycine polyacrylamide gel and stained with Coo-
massie brilliant blue R, and then immunoblotting analyses with
anti-NAGA and anti-GLA polyclonal antibodies were performed.
The results showed that there was no immunological cross-reac-
tivity between the modiﬁed NAGA and the recombinant GLAs,
i.e., agalsidase beta and agalsidase alfa. Figure labels are as follows:
Coomassie blue, staining of the gel with Coomassie brilliant blue R;
Anti-NAGA, immunoblotting with anti-NAGA polyclonal anti-
bodies; and Anti-GLA, immunoblotting with anti-GLA polyclonal
antibodies.
Table 4. Monosaccharide Analysis of the Modified NAGA
Modified
NAGA
Agalsidase
Beta
Agalsidase
Alfa
N-Acetylglucosamine 34 5 2.0 19 5 8.0 18 5 4.0
Mannose 44 5 14 24 5 14 24 5 3.0
Fucose 6.55 0.6 3.5 5 1.6 4.1 5 0.6
Galactose 13 5 0.2 11 5 6.4 12 5 1.8
Mannose 6-phosphate 5.15 1.2a 3.6 5 2.2 2.1 5 0
Sialic acid 1.15 0.4 6.1 5 0.2 4.8 5 0.8
All data are expressed as means5 SD (n ¼ 4). As controls, agalsidase beta and
agalsidase alfa were used.
a The mannose 6-phosphate content of the modified NAGA is higher than that
of agalsidase beta or agalsidase alfa (p < 0.05, t test).er 13, 2009
Morphological analysis revealed that many lamellar
inclusion bodies, including deposits of Gb3, were present
in Kupffer cells of the liver, renal tubular cells of the
kidneys, and pericytes of the heart and that they were
markedly decreased after repeated administration of the
modiﬁed NAGA, as in the cases of agalsidase beta and agal-
sidase alfa (Figure 9).
Discussion
Repeated administration of recombinant GLAs to male
patients with Fabry disease frequently causes infusion reac-
tions, mainly allergic ones,4,5 because most male Fabry
patients do not have any GLA proteins. IgG antibodies to
recombinant GLAs develop in the majority of male Fabry
patients treated with these recombinant GLAs32,although
female Fabry patients having some GLA proteins rarely
develop antibodies to the enzymes. It has been reported
that even the development of IgE antibodies can occur.33
These antibodies probably decrease the effect of ERT for
Fabry disease.8–10
Figure 4. Stability of theModifiedNAGA
The modiﬁed NAGA was added to buffers
of the indicated pH values and incubated
at 37C for 16 hr, and then MU-a-D-galac-
topyranoside-degrading activity was deter-
mined (A). We examined the stability of
the modiﬁed NAGA under pH 4.5 (B) and
pH 7.0 (C) conditions in a buffer and in
plasma (D) at 37C by following the time
course after the addition of the enzyme
to the buffers and plasma. As controls,
agalsidase beta and agalsidase alfa were
used. Error bars represent means 5 SD
(n ¼ 3). The modiﬁed NAGA is more stable
than the recombinant GLAs. *p < 0.01 in
comparisons to both agalsidase beta and
agalsidase alfa; **p < 0.05 in comparisons
to both agalsidase beta and agalsidase
alfa, t test.
We therefore paid attention to
NAGA.NAGA catalyzes the hydrolysis
of the terminal a-N-acetylgalactos-
amine of glycoconjugates, including
polysaccharides, glycolipids, and
glycoproteins.11,34 Human NAGA
and GLA genes exhibit remarkable
homology of their predicted amino
acid sequences, and a deﬁciency of
NAGA leads to very rare genetic
diseases, i.e., Schindler disease (MIM
609241) and Kanzaki disease (MIM
609242), neurological and skin disor-
ders, respectively.34 Their substrate
speciﬁcities differ only in the presence
of an N-acetyl or hydroxyl moiety,
respectively, at position 2 of the galac-
tose ring. GLA and NAGA resemble
each other in structure, but their immunogenicities are
different, and there is no immunological cross-reactivity
between them.35,36 Therefore, we compared a homology
model of human NAGAwith the crystallographic structure
ofhumanGLAandpredictedaminoacid residues that could
alter the substrate speciﬁcity of NAGA to that of GLA. On
the basis of the results of structural analysis, we designed
a modiﬁed NAGA with two amino acid substitutions,
Ser188Glu and Ala191Leu, and an expression study
revealed that the modiﬁed NAGA strongly degraded MU-
a-D-galactopyranoside, one of the preferred substrates of
GLA (Table 1).
Because the whole structure of themodiﬁed NAGA is not
altered, although the substrate-recognition region inside
the molecule is moderately changed, the administration
of the modiﬁed NAGA to Fabry patients, who usually
have endogenous NAGA protein, should hardly cause an
allergic reaction to administered modiﬁed NAGA. It is
known that NAGA is heat stable, i.e., that GLA loses
approximately 80% of its activity but NAGA retains more
than 50% of its activity when heated to 55C in pH 6–7The American Journal of Human Genetics 85, 569–580, November 13, 2009 575
buffer for approximately 30 min.11 Furthermore, the
number of sugar chains attached to NAGA (10 mol/mol
protein)37 is larger than the number attached to GLA
(6 mol/mol protein).1 So, the modiﬁed NAGA is expected
to have clinical advantages for ERT for Fabry disease.
First, we generated stable CHO cell lines expressing the
modiﬁed NAGA. To enhance the secretion of the modiﬁed
NAGA into the culture medium, we replaced its signal
sequence with that of GLA because the modiﬁed NAGA
with its own signal sequence was retained in cells (data
not shown). The productivity of the modiﬁed NAGA is
10 mg/liter under the culture conditions on a laboratory
scale, and it could be further improved by the development
of an industrial production system in the future.
A puriﬁcation study followed by biochemical character-
ization revealed that the modiﬁed NAGA was an N-glyco-
protein having heterogeneous sugar chains (Figure 2) and
Figure 5. Immune Reaction of the Modified NAGA to Serum
from a Fabry Patient
We performed ELISA to determine whether the modiﬁed NAGA
immunologically reacted to serum from a Fabry patient who had
been repeatedly injected with agalsidase beta. Although the serum
(titer of the antibodies against GLA, 12,8003) strongly reacted to
agalsidase beta and agalsidase alfa, it did not react to the modiﬁed
NAGA. Open columns: 1,0003 diluted patient’s serum. Closed
columns: 10,0003 diluted patient’s serum. ND: Not detected. Error
bars represent means5 SD (n ¼ 3).576 The American Journal of Human Genetics 85, 569–580, Novemthat its M6P residue content was higher than that of agal-
sidase beta or agalsidase alfa (p < 0.05, t test, Table 4).
Because M6P residues are essential for the incorporation
of a modiﬁed NAGA into cells via M6P receptors on the
cell membrane (Figure 6), as in the cases of recombinant
GLAs,38,39 a modiﬁed NAGA having many M6P residues
would be beneﬁcial for ERT. Furthermore, the modiﬁed
NAGA was more stable than agalsidase beta and agalsidase
alfa both in buffers (p < 0.05, t test, Figures 4A–4C) and in
human plasma (p < 0.05, t test, Figure 4D), as expected.
This would also be beneﬁcial for ERT. Immunological
examinations revealed that the modiﬁed NAGA did not
cross-react with recombinant GLAs (Figure 3) and that it
did not react to the serum from a Fabry patient who had
been repeatedly injected with agalsidase beta (Figure 5).
Regarding the speciﬁc activity of the modiﬁed NAGA, it
was lower than those of the recombinant GLAs. This might
be due to the small differences in the structures of the
active-site pocket and the surface of the molecule between
themodiﬁed NAGA and the GLAs because the structures of
these regions should be associated with substrate recogni-
tion. This would be disadvantageous for a modiﬁed
NAGA. The lysosomal degradation of Gb3 requires saposin
B, a nonenzymic activator that presents Gb3 to the cata-
lytic site of GLA.40 Because saposin B is essentially required
for enzymic Gb3 degradation in cells, it may also play
a role in the degradation of Gb3 by a modiﬁed NAGA.
Coadministration of saposin B with the modiﬁed NAGA
might accelerate its degradation of the Gb3 accumulated
in Fabry cells.
After conﬁrmation of the effect of the modiﬁed NAGA
on cultured Fabry ﬁbroblasts (Figure 6), we injected the
modiﬁed NAGA into Fabry mice and examined both the
incorporation of the enzyme into organs and its Gb3-
degrading activity. The modiﬁed NAGA was successfully
incorporated into the liver, kidneys, and heart, the Gb3
deposited in these organs was apparently cleaved or
decreased (Figure 8 and Table 5), and the speciﬁc patholog-
ical changes were improved (Figure 9), as in the cases of the
administration of the recombinant GLAs.Figure 6. Immunostaining for the Gb3 Accumulated in Fabry Fibroblasts
Cultured Fabry ﬁbroblasts were stained with anti-Gb3 mAb after addition of the modiﬁed NAGA (Modiﬁed NAGA), the modiﬁed NAGA
and 5 mM M6P (Modiﬁed NAGAþM6P), agalsidase beta (Agalsidase beta), or agalsidase alfa (Agalsidase alfa). As controls, wild-type cells
(Wild-type) and untreated Fabry cells (Fabry) were examined. Each of the enzymes was added to the culture medium to give a concentra-
tion of 5 mmol/h/ml, and the cells were cultured for 72 hr. The Gb3 that had accumulated in Fabry ﬁbroblasts was cleaved on adminis-
tration of the modiﬁed NAGA as well as the recombinant GLAs, but not on coadministration of the modiﬁed NAGA and M6P. The scale
bar represents 50 mm.ber 13, 2009
In conclusion, we produced a modiﬁed NAGA exhibit-
ing catalytic activity toward Gb3 and MU-a-D-galactopyr-
anoside by means of a structure-based design. The enzyme
has many advantages because of its high stability and
high M6P content and the low possibility of the
occurrence of an allergic reaction, although these
Figure 7. MU-a-D-Galactopyranoside-Degrading Activity (nmol/h/mg protein) in Organs from Fabry Mice Treated with a Single
Dose of the Modified NAGA, Agalsidase Beta, or Agalsidase Alfa
Fabry mice were injected with a single dose (2 mmol/h/kg body weight) of each of the enzymes and then sacriﬁced 1 hr after the admin-
istration.Wild-type,wild-type mice; Fabry, untreated Fabry mice;Modiﬁed NAGA, Fabry mice treated with the modiﬁed NAGA; Agalsidase
beta, Fabrymice treated with agalsidase beta; and Agalsidase alfa, Fabrymice treated with agalsidase alfa. Error bars representmeans5 SD
(n¼ 3). The increases in the enzyme activity upon administration of the modiﬁed NAGA are greater in the kidneys (p¼ 0.005 and 0.003
in comparison to agalsidase beta and agalsidase alfa, respectively, t test) and heart (p ¼ 0.001 and 0.003 in comparison to agalsidase beta
and agalsidase alfa, respectively, t test) tissues than in the cases of the recombinant GLAs.
Figure 8. Immunohistochemical Analyses of the Accumulated Gb3 in Organs of Fabry Mice and Its Degradation by the Modified
NAGA, Agalsidase Beta, and Agalsidase Alfa
Fabry mice were repeatedly injected with the modiﬁed NAGA, agalsidase beta, or agalsidase alfa, and then immunostaining for Gb3 was
performed. Wild-type, a wild-type mouse; Fabry, an untreated Fabry mouse; Modiﬁed NAGA, a Fabry mouse treated with the modiﬁed
NAGA; Agalsidase beta, a Fabry mouse treated with agalsidase beta; and Agalsidase alfa, a Fabry mouse treated with agalsidase alfa.
The scale bar represents 50 mm.The American Journal of Human Genetics 85, 569–580, November 13, 2009 577
characteristics should be conﬁrmed in future clinical
studies. The modiﬁed NAGA is highly promising as a
new enzyme for ERT for Fabry disease, and such struc-
ture-based design of modiﬁed lysosomal enzymes should
be useful for the development of ERT for lysosomal
storage diseases.
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